Toll-like receptor 4 mediates blood-brain barrier permeability and disease in C3H mice during Venezuelan equine encephalitis virus infection

Venezuelan equine encephalitis virus and toll-like receptor 4

Bradley S. Hollidge a,c, Courtney A. Cohen a, Justice Akuoku Frimpong a,d, Catherine V. Badger a, John M. Dye a, and Connie S. Schmaljohn b,e

Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA; b Headquarters Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA; c REGENXBIO, Inc., Rockville, Maryland, USA; d Immunodiagnostics Department, Biological Defense Research Directorate, Naval Medical Research Center, Fort Detrick, Maryland, USA; e Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institute of Health, Fort Detrick, Maryland, USA

ABSTRACT

Venezuelan equine encephalitis virus (VEEV) is an encephalitic alphavirus that can cause debilitating, acute febrile illness and potentially result in encephalitis. Currently, there are no FDA-licensed vaccines or specific therapeutics for VEEV. Previous studies have demonstrated that VEEV infection results in increased blood-brain barrier (BBB) permeability that is mediated by matrix metalloproteinases (MMPs). Furthermore, after subarachnoid hemorrhage in mice, MMP-9 is upregulated in the brain and mediates BBB permeability in a toll-like receptor 4 (TLR4)-dependent manner. Here, we demonstrate that disease in C3H mice during VEEV TC-83 infection is dependent on TLR4 because intranasal infection of C3H/HeN (TLR4 WT) mice with VEEV TC-83 resulted in mortality as opposed to survival of TLR4-defective C3H/HeJ (TLR4 mut) mice. In addition, BBB permeability was induced to a lesser extent in TLR4 mut mice compared with TLR4 WT mice during VEEV TC-83 infection as determined by sodium fluorescein and fluorescently-conjugated dextran extravasation. Moreover, MMP-9, MMP-2, ICAM-1, CCL2 and IFN-γ were all induced to significantly lower levels in the brains of infected TLR4 mut mice compared with infected TLR4 WT mice despite the absence of significantly different viral titers or immune cell populations in the brains of infected TLR4 WT and TLR4 mut mice. These data demonstrate the critical role of TLR4 in mediating BBB permeability and disease in C3H mice during VEEV TC-83 infection, which suggests that TLR4 is a potential target for the development of therapeutics for VEEV.

ARTICLE HISTORY

Received 24 August 2020 Revised 30 November 2020 Accepted 24 December 2020

KEYWORDS
Venezuelan equine encephalitis virus; blood-brain barrier; toll-like receptor 4; veev; tlr4

Introduction

Venezuelan equine encephalitis virus (VEEV) is an arthropod-borne virus (arbovirus) in the Alphavirus genus of the Togaviridae family and is one of the New World alphaviruses, which are mostly encephalitogenic [1,2]. This single-stranded, positive-sense RNA virus has sporadically caused widespread epidemics and epizootics in the Western Hemisphere as it is highly pathogenic for both humans and equines [1,3]. The incubation period of VEEV in humans is approximately 1–8 days after infection and VEEV infection in humans typically results in an asymptomatic infection or an acute, febrile illness with malaise, severe retro-orbital or occipital headaches, myalgia, nausea and vomiting as common features [3,4]. Even though the case-fatality rate is low (<1%), disease caused by VEEV infection can also progress to the central nervous system (CNS) in 4–14% of human cases resulting in neurologic disease [3]. The encephalitic disease is variable in severity ranging from somnolence and mild confusion to seizures, ataxia, paralysis and coma [5]. As a result of it producing incapacitating or lethal infections and being infectious by aerosols as well as its ease of being grown to high titers in elementary cell culture systems, VEEV represents a significant potential biologic threat [6]. VEEV is classified as a category B priority biodefense agent by both the Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases. Currently, there are no approved vaccines or specific therapies for VEEV. As evidenced by the occurrence of laboratory-acquired infections involving aerosols, aerosolized VEEV is highly infectious to humans, potentially resulting in higher mortality than natural infections [7,8].

In murine models, VEEV rapidly enters the CNS following aerosol or intranasal exposure via the
olfactory neuroepithelium and olfactory bulb where it initially replicates [9–11]. In addition, intranasal inoculation of VEEV replicon particles, which undergo only a single round of replication with no propagation or spread, induces an inflammatory cascade and an increase in blood-brain barrier (BBB) permeability [12]. Despite the restriction of viral RNA to the olfactory bulb, the increased BBB permeability is disseminated throughout the brain suggesting the propagation of a signal in the brain that induces an increase in BBB permeability. Furthermore, treatment of VEEV-infected mice with a broad-spectrum matrix metalloproteinase (MMP) inhibitor reduced the induction of BBB permeability during infection, delayed onset of disease and reduced mortality [12]. These findings complement studies of West Nile virus (WNV) and Rift Valley fever virus implicating MMP-9 in mediating BBB permeability [13,14] and demonstrate that increased BBB permeability is a critical step in the neuropathogenesis of these encephalitic viruses.

Innate immune signaling within the CNS can alter BBB permeability in the context of infection [15] or injury (e.g. cerebral ischemia) [16] through the induction of cytokines, chemokines and neurovascular proteases including MMPs. In particular, upregulation of MMP-9 results in increased BBB permeability [12,14,16–19], vasogenic edema [20,21] and hemorrhage [22,23]. Recently, inhibition of toll-like receptor 4 (TLR4) was found to prevent the induction of increased BBB permeability and suppress the upregulation of MMP-9 after subarachnoid hemorrhage in mice [16]. Additionally, upregulation of MMP-9 has also been reported to be dependent on TLR2 in intracerebral hemorrhage models [24]. Moreover, high-mobility group box 1 (HMGB1) is released resulting in TLR4-dependent MMP-9 upregulation in the brain following cerebral ischemia in mice [25]. Taken together, these studies demonstrate a role for innate immune signaling in the induction of BBB permeability.

In addition, the innate immune system in the CNS provides potential targets for treatment of VEEV since modulation of the innate immune system can alter the lethality of virus infections. For example, TLR4-knockout mice infected with Japanese encephalitis virus (JEV) show reduced CNS inflammation, viral RNA, leukocyte infiltration, proinflammatory cytokine expression and, importantly, increased resistance to lethal infection [26]. In addition, TLR2 mediates the induction of inflammatory cytokines and mortality in mice infected with herpes simplex virus 1 [27]. Therefore, TLRs play a central role in the pathogenesis of neurotropic viruses.

Here, we investigated the role of TLR4 in the induction of BBB permeability and disease in mice during VEEV infection using the C3H/HeN model of VEEV infection with the TC-83 vaccine strain, which causes encephalitis and death in C3H/HeN (TLR4<sup>WT</sup>) mice when intranasally instilled, in parallel with TLR4-defective C3H/HeJ (TLR4<sup>mut</sup>) mice.

**Materials and methods**

**Virus**

The live-attenuated VEEV vaccine TC-83 (NDBR-102, lot 4, run 3; National Drug Company, Swiftwater, PA, USA) was passaged twice in BHK cells before sucrose purification.

**Ethics statement**

Research was conducted under an Institutional Animal Care and Use Committee (IACUC)-approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to animals and experiments involving animals. The facility where this research was conducted is accredited by the AAALAC International and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011.

**Animal experiments**

C3H/HeN (TLR4<sup>WT</sup>) mice were purchased from Jackson Laboratories and C3H/HeJ (TLR4<sup>mut</sup>) mice were purchased from Charles River Laboratories. In all studies, 6–8 week-old female mice were intranasally instilled (20 µL per nostril) with 2 × 10<sup>7</sup> plaque-forming units (PFU) of VEEV TC-83 in 40 µL phosphate-buffered saline (PBS) or 40 µL PBS alone under light isoflurane anesthesia. Mice were weighed daily and monitored 1–3 times per day for survival and signs of disease.

**BBB permeability assessment**

To assess BBB permeability, mice were injected intraperitoneally with 10 mg of sodium fluorescein salt (Sigma-Aldrich) or 400 µg of 3kDa-dextran conjugated to Alexa Fluor 680 (Invitrogen) in sterile PBS. Approximately 40 min after this injection, mice were anesthetized with ketamine-acepromazine-xylazine for approximately 5 min until unresponsive. Blood was collected by a terminal cardiac bleed followed by cardiac perfusion with PBS. Serum was isolated using a serum separator and was stored at −80°C for
subsequent analysis. Brains were harvested and stored at −80°C until homogenization. One hemisphere of each brain from mice that were administered 3kDa-dextran conjugated to Alexa Fluor 680 was fixed in formalin and Alexa Fluor 680 fluorescence was imaged using a Licor Odyssey CLx (Li-cor Biosciences).

Each brain region was homogenized in 1 mL of PBS using GentleMACS M tubes (Miltenyi Biotec). Sodium fluorescein and Alexa Fluor 680 fluorescence in brain homogenates were measured undiluted or diluted in PBS. To measure sodium fluorescein in the brain, homogenates were diluted 1:1 with 2% trichloroacetic acid (Thermo Scientific) to precipitate protein and incubated at 4°C overnight, centrifuged at 3,000 rpm for 10 min, and then supernatants were diluted 1:1 with borate buffer (0.05 M, pH 11; Ricca Chemical). Sample fluorescence of fluorescein (excitation at 480 nm; emission at 538) or Alexa Fluor 680 (excitation at 679; emission 702) was measured using a Tecan Infinite M1000 Pro microplate reader. The amount of fluorescein in each tissue sample and serum sample was determined using standards ranging from 3.7 μg to 3750 μg in 0.025 M borate buffer and 1% thichloroacetic acid. The tissue fluorescein was normalized to tissue weight and the BBB permeability was determined as the ratio of the amount of sodium fluorescein measured in the brain region to the amount measured in the serum for each mouse. The relative BBB permeability is expressed as the BBB permeability of infected mice normalized to the BBB permeability of uninfected mice of the same genotype.

**Plaque assays**

In six-well plates, Vero 76 cells were plated at a density of 3 x 10^5 cells/well and incubated for 48 h at 37°C, 5% CO₂. Serial dilutions of tissue homogenates were made in 1x Minimum Essential Medium with 1% penicillin/streptomycin and 10% (v/v) heat-inactivated fetal bovine serum (HI-FBS). The serially-diluted homogenates were incubated on the Vero cell monolayers for 1 h at 37°C, 5% CO₂ with gentle rocking every 15 min. Subsequently, cells were overlaid with 2 ml of a 1:1 mixture of 1% (w/v) agarose and 2X Basal Medium Eagle with Earle’s Salts (EBME) containing 10% HI-FBS, 2% penicillin/streptomycin, 50 μg/mL gentamicin, and 2.5 μg/mL Fungizone (amphotericin B). The plates were incubated overnight with the 0.5% agarose/EBME overlay at 37°C, 5% CO₂. After approximately 24 h, 2 ml of a secondary 0.5%/EBME overlay with 4% neutral red was added to each well and then incubated overnight at 37°C, 5% CO₂. The visualized plaques were counted.

**Magpix multiplex assays**

The concentration of CCL-2, ICAM-1, MMP-2, MMP-9, IL-2, IL-4, IL-6, TNF-α and IFN-γ in the brain homogenates were determined with multiplex magnetic bead-based immunoassays (mouse magnetic Luminex assay [R&D Systems] – CCL-2, ICAM-1, MMP-2 and MMP-9; high sensitivity 5-plex mouse ProcartaPlex panel [Invitrogen] – IL-2, IL-4, IL-6, TNF-α and IFN-γ) according to the manufacturers’ instructions. The samples were analyzed using a MAGPIX analyzer (Luminex Inc.).

**Serum IFN-γ ELISA**

IFN-γ concentrations were determined using a Quantikine mouse IFN-γ ELISA (R&D Systems) and according to the manufacturer’s instructions.

**Flow cytometry**

Brain homogenates were prepared as previously described [28]. Briefly, tissue was incubated at 37°C for 45 min in digestion buffer (1% FBS, 1 mg/ml collagenase D, 0.1 mg/ml DNase in RPMI) and then homogenized using the GentleMACS Dissociator system (Miltenyi Biotec). Mononuclear cell suspensions were isolated by filtering homogenate through a 70 μm cell strainer and then centrifuging on a 30/70% Percoll gradient for 30 min at 4°C. Immune cells were collected from the interface, stained with amine-reactive Aqua fixable dye (Thermo Fisher) to exclude dead cells, and nonspecific staining was restricted by using rat anti-mouse CD16/CD32 (BD Biosciences). Cells were surface stained for conventional immune cell markers, and then fixed, permeabilized and stained for intracellular cytokine analysis. Cell types were defined as follows: Resting microglia (CD45<sup>low</sup>CD11b<sup>low</sup>), activated microglia (CD45<sup>high</sup>CD11b<sup>low</sup>Ly6C<sup>Ly6G</sup>), T cells (CD45<sup>high</sup>CD3<sup>+</sup>), B cells (CD45<sup>high</sup>CD19<sup>+</sup>), infiltrating macrophages (CD45<sup>high</sup>CD11b<sup>+</sup>CD11c<sup>−</sup>Ly6C<sup>−</sup>Ly6G<sup>−</sup>), inflammatory monocytes (CD45<sup>high</sup>CD11b<sup>−</sup>CD11c<sup>−</sup>MHCcII<sup>Ly6C<sup>−</sup></sup>Ly6G<sup>−</sup>SSC<sup>high</sup>), non-classical monocytes (CD45<sup>high</sup>CD11b<sup>−</sup>CD11c<sup>−</sup>MHCcII<sup>Ly6C<sup>−</sup></sup>Ly6G<sup>−</sup>SSC<sup>high</sup>), polymorphonuclear neutrophils (CD45<sup>high</sup>CD11b<sup>−</sup>CD11c<sup>−</sup>MHCcII<sup>Ly6C<sup>−</sup></sup>Ly6G<sup>−</sup>), natural killer cells (CD45<sup>high</sup>CD11b<sup>low</sup>CD11c<sup>−</sup>MHCcII<sup>CD49b<sup>−</sup>SSC<sup>low</sup></sup>), and dendritic cells (CD45<sup>high</sup>CD11b<sup>−</sup>CD11c<sup>−</sup>). Samples were acquired on a Fortessa X20 flow cytometer (BD Biosciences) with FACS Diva software, and analyzed using Flowjo (Treestar, version X).

**Statistical analysis**

Kaplan-Meier survival curves were analyzed by the log-rank test. The statistical significance of all other data was evaluated by unpaired two-tailed Student’s t-tests or Mann-Whitney tests. A p-value of <0.05 was considered significant. All data are expressed as the mean ±
standard error of the mean (SEM). Statistical analysis was performed using GraphPad Prism 8 software. Data shown have been confirmed in independent experiments (data not shown) with the exception of flow cytometry experiments.

Results

TLR4mut mice are less susceptible to disease during VEEV TC-83 infection

Previous studies have shown that VEEV replication in the CNS precedes the increase in BBB permeability and that inhibition of MMPs decreases the induced BBB permeability as well as increases survival times and survival rates of mice challenged subcutaneously [12]. In addition, MMP-9 is upregulated in a number of neurologic diseases [12,14,17,19–22,24], which can be mediated by TLR4 [16,25]. Moreover, C3H/HeN (TLR4 WT) mice are susceptible to intranasal exposure of VEEV TC-83 and develop encephalitic disease [11,29,30], unlike other inbred mouse strains. Conveniently, the C3H/HeJ substrain (TLR4mut) of C3H mice, which was characterized as LPS hyporesponsive, has a single point mutation in the Trlr4 gene that results in a defective TLR4 protein [31]. Therefore, to determine if TLR4 alters the susceptibility of C3H mice to intranasal exposure of VEEV TC-83, TLR4 WT mice and TLR4mut mice were intranasally instilled with 2 x 10^7 PFU and were subsequently monitored for disease and survival. As expected, a majority of the TLR4 WT mice that were intranasally infected with VEEV TC-83 succumbed to the infection with a mortality rate of 60% and a mean time-to-death of 9.8 days (Figure 1a). These TLR4 WT mice began losing weight at day 6 post-infection (PI), which continued until day 9 (−25.1 ± 3.2% baseline weight; Figure 1b), at which point the mice began to succumb to disease. The surviving TLR4 WT mice lost an average of 19.7 ± 2.1% of their baseline bodyweight during peak disease. In contrast to the TLR4 WT mice, 100% of the TLR4mut mice survived VEEV TC-83 infection (Figure 1a; p = 0.0041, log-rank test). Moreover, these mice began to lose weight at day 6 PI (−0.6 ± 1.4% baseline weight), peaked at day 7 (−3.1 ± 1.3% baseline weight), and then began to regain weight (Figure 1b). Other than weight loss, the TLR4mut mice showed no overt signs of disease.

Despite the significant differences in mortality and disease, there were no significant differences in the viral loads in the brains at days 1, 2, 4, 6 or 8 PI between the two mouse substrains (Figure 1c-f). These data indicate that the encephalitic disease observed in mice infected with VEEV TC-83 is not exclusively dependent on viral load.

TLR4 mediates BBB permeability during VEEV TC-83 infection

To determine the dependence of increased BBB permeability during VEEV TC-83 infection, BBB integrity was measured by the extravasation of sodium fluorescein (NaF) in different brain regions. At days 1, 2, 4, 6 and 8 PI, TLR4 WT mice and TLR4mut mice were intra-peritoneally injected with NaF. After 45 min, sera and perfused brains were harvested and the brains were assessed for BBB permeability by measuring the amount of NaF in the brains relative to the sera. In the olfactory bulb, BBB permeability began to increase in the TLR4 WT mice at day 2 PI and continued to increase until day 4 PI, after which BBB permeability began to decrease and return to baseline at day 8 PI. However, the BBB permeability in the olfactory bulbs at day 4 PI in TLR4mut mice was induced to a lower level compared with infected TLR4 WT mice (Figure 2a). More strikingly, the VEEV TC-83-induced BBB permeability in the cortexes of TLR4mut mice was induced to significantly lesser extents at days 4, 6 and 8 PI compared with infected TLR4 WT mice (Figure 2b). The induction of BBB permeability in the cerebellums (Figure 2c) and brainstems (Figure 2d) of both strains of mice was lower compared to the permeabilities of the olfactory bulbs and cortexes. To confirm the role of TLR4 in BBB permeability during VEEV TC-83 infection found by NaF extravasation, TLR4 WT and TLR4mut mice were injected with 3kDa-dextran conjugated to Alexa Fluor 680 (DEX-680) at day 6 PI. As shown in (Figure 2e,f), BBB permeability was induced to a significantly lesser extent in the infected TLR4mut mice compared with the infected TLR4 WT mice. These data demonstrate that TLR4 mediates increased BBB permeability during VEEV TC-83 infection.

Impaired TLR4 signaling reduces the upregulation of BBB permeability-related proteins during VEEV TC-83 infection

Several proteins involved in BBB permeability were measured in the cortexes of TLR4 WT and TLR4mut mice infected with VEEV TC-83. MMP-9 was of particular interest because its expression can be dependent on TLR4 in the brain [16,25] and it can disrupt the BBB by degrading tight junction proteins and basal lamina proteins. Furthermore, MMP-9 has been shown to mediate increased BBB permeability in neurologic diseases, including during WNV infection [14] and VEEV infection of mice [12]. As expected, there was a significant upregulation of MMP-9 in the cortexes of TC-83-infected TLR4 WT mice at days 4, 6 and 8 PI,
Figure 1. Survival, weight change and brain viral titers in TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice during VEEV TC-83 infection. TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice were intranasally instilled with 2 × 10<sup>3</sup> PFU of VEEV TC-83 (n = 10 mice per group) or PBS (n = 5 mice per group). Mice were monitored for survival (a) and weight change (b). The viral titers in the brains of TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice were determined by plaque assay from the olfactory bulb (c), cortex (d), cerebellum (e) and brainstem (f). Data are presented as mean ± SEM (n = 3–5 mice per group). The dotted line represents the limit of detection for the lowest dilution tested. Statistically significant differences between infected TLR4<sup>WT</sup> and TLR4<sup>mut</sup> are indicated as *, P < 0.05; **, P < 0.01 and #, P < 0.0001. Kaplan-Meier survival curves were analyzed by the log-rank test. The statistical significance of all other data was evaluated by unpaired two-tailed Student’s t-tests or Mann-Whitney tests.

which coincides with increased cortical BBB permeability, compared with mock-infected TLR4<sup>WT</sup> mice. However, there was no significant upregulation in MMP-9 in the cortices of TC-83-infected TLR4<sup>mut</sup> mice compared with mock-infected TLR4<sup>mut</sup> mice. Furthermore, MMP-9 was induced to significantly lesser extents in the cortices of infected TLR4<sup>mut</sup> mice compared with the TLR4<sup>WT</sup> mice (Figure 3a). In addition, there were significant inductions of MMP-2 in the brains of both TLR4<sup>WT</sup> and TLR4<sup>mut</sup> mice infected with VEEV TC-83 compared with uninfected mice. However, the induction of MMP-2 in infected TLR4<sup>mut</sup> mice was significantly lower compared with the infected TLR4<sup>WT</sup> mice at days 4 and 6 PI (Figure 3b).

Intracellular adhesion molecule 1 (ICAM-1) is constitutively expressed at low levels on the vascular endothelium of the BBB and perivascular astrocytes. However, ICAM-1 is upregulated in pathological conditions in the brain and plays an important role in cell-cell adhesion, extravasation and inflammatory responses [32]. Even though ICAM-1 was significantly induced in the brains of both infected TLR4<sup>WT</sup> and TLR4<sup>mut</sup> mice at days 4, 6 and 8 PI, it was induced to
**Figure 2.** BBB permeability in TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice during VEEV TC-83 infection. The changes in BBB permeability in VEEV TC-83-infected TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice were assessed by measuring the uptake of NaF in the olfactory bulbs (a), cortices (b), cerebellums (c) and brainstems (d). The uptake of DEX-680 in the cortices of TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice were determined at day 6 PI (e) and visualized by imaging on a near-infrared imager (f). Tissue uptake of NaF or DEX-680 for each brain region was the ratio of the amount of fluorophore in each region to the amount of fluorophore in the serum for each mouse. NaF and DEX-680 uptake is expressed as the fold change over uninfected control mice of the same genotype. Higher fluorophore uptake represents increased BBB permeability. Mock-infected (PBS-instilled) mice are represented as Day 0 PI. Data are presented as mean ± SEM (n = 3–5 mice per group). Statistically significant differences are indicated as *, p < 0.05; **, p < 0.01. Statistical significance was evaluated by unpaired two-tailed Student’s t-tests or Mann-Whitney tests.

Significantly lower extents in the cortices of infected TLR4<sup>mut</sup> mice (Figure 2c).

Furthermore, C-C motif ligand 2 (CCL-2) was significantly induced in the cortices of both infected TLR4<sup>WT</sup> and TLR4<sup>mut</sup> mice. However, CCL-2 was significantly less induced in the TLR4<sup>mut</sup> mice compared with the TLR4<sup>WT</sup> mice at days 4 and 6 PI, but was induced to similar levels at day 8 PI (Figure 3d). CCL-2 attracts monocytes and T cells as well as contributes to BBB permeability [33]. The reduced inductions of MMP-9, MMP-2, CCL-2 and ICAM-1 in the TLR4<sup>mut</sup> mice support the role of TLR4 mediating BBB permeability during VEEV infection.

*Induction of inflammatory cytokines in the brains of mice is not mediated by TLR4 during VEEV TC-83 infection*

In order to determine the effects of TLR4 signaling in the brain on the inflammatory cytokine response during VEEV TC-83 infection, the levels of interleukin 2 (IL-2), IL-4, IL-6 and tumor necrosis factor alpha
IFN-γ is less induced in the brains of VEEV TC-83-infected TLR4mut mice

Interferon gamma (IFN-γ), the only member of the type II class of IFNs, is a dimerized soluble cytokine that is released predominately by leukocyte subtypes, such as natural killer (NK) cells, Th1 cells and cytotoxic T lymphocytes. Importantly, IFN-γ is also a mediator of BBB permeability during CNS infections [34,35]. There was a significant induction of IFN-γ in the brains of both TLR4WT and TLR4mut mice infected with VEEV TC-83. However, IFN-γ was induced to a lesser extent in the cortices of infected TLR4mut mice compared with infected TLR4WT mice at days 4, 6 and 8 PI (Figure 5a). In addition, day 6 PI was the only day with a significant induction of IFN-γ in the serum of infected mice and these levels of induction were significantly less than in the brains of infected TLR4mut mice compared with infected TLR4WT mice (Figure 5b). These data demonstrate that defective TLR4 signaling impairs IFN-γ induction in the brains of TC-83-infected mice.

Loss of TLR4 signaling does not alter the immune population in the brain during TC-83 infection

To determine if defective TLR4 signaling alters the immune cell population in the brains of TC-83-infected mice, brain homogenates were stained for...
Figure 4. Induction of IL-2, IL-4, IL-6 and TNF-α in the cortices of TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice during VEEV TC-83 infection. The induction of IL-2 (a), IL-4 (b), IL-6 (c) and TNF-α (d) during VEEV TC-83 infection was assessed in cortical tissue from TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice. The fold change of these proteins is expressed as the ratio of the amount of protein in infected mice relative to uninfected mice of the same genotype. Mock-infected (PBS-instilled) mice are represented as Day 0 PI. Data are presented as mean ± SEM (n = 3–5 mice per group). Statistically significant differences are indicated as *, p < 0.05. Statistical significance was evaluated by unpaired two-tailed Student’s t-tests or Mann-Whitney tests.

Figure 5. IFN-γ induction in the cortices and sera of TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice during VEEV TC-83 infection. The induction of IFN-γ in the cortices (a) and sera (b) during VEEV TC-83 infection was assessed in TLR4<sup>WT</sup> mice and TLR4<sup>mut</sup> mice. The fold change of IFN-γ is expressed as the ratio of the amount of IFN-γ in infected mice relative to uninfected mice of the same genotype. Mock-infected (PBS-instilled) mice are represented as Day 0 PI. Data are presented as mean ± SEM (n = 3–5 mice per group). Statistically significant differences are indicated as *, p < 0.05; **, p < 0.01. Statistical significance was evaluated by unpaired two-tailed Student’s t-tests or Mann-Whitney tests.
flow cytometry analysis on day 6 PI when the differences in MMP-9, ICAM-1, CCL-2 and IFN-γ induction were greatest (Figure [3,5]). There were no differences in the numbers or percentages of CD45 hi leukocytes (Figure 6(a,b)) or NK cells (Figure 6(c,d)) in the brains of infected TLR4 WT and TLR4 mut mice. There was a significant increase in the number of B cells (CD45 hiCD19 hi) in the infected TLR4 mut mice compared with the infected TLR4 WT mice despite there being no significant difference in the percentage of CD45 hi leukocytes that are B cells (Figure 6(e,f)). However, there were no significant differences in the percentage or number of T cells (CD45 hiCD3+ 3) (Figure 6(e,f)), whether CD4+ or CD8+ (Figure 6(g,h)). Furthermore, there were no detectable differences in T cell activation (CD69+ 4) or intracellular IFN-γ expression (Figure 6(i,j)) between the two mouse strains.

There were also no significant differences in myeloid/microglial immune populations between infected TLR4 WT and TLR4 mut brains. Analysis included dendritic cells, macrophages, polymorphonuclear neutrophils, inflammatory monocytes, non-classical monocytes, activated microglia and resting microglia (Figure 7(a,b)). In addition, there were no preexisting differences in CNS leukocytes populations between the two substrains.

**Discussion**

Encephalitis is a serious and potentially fatal outcome of human VEEV infection; however, the mechanisms in the CNS that drive neurologic disease during VEEV infection are ill-defined. This lack of understanding coupled with the absence of approved vaccines for human use and specific therapies for VEEV infection underscores the need for determining the neuropathogenic mechanisms of encephalitic alphaviruses. During VEEV infection in the CNS, the induction of BBB permeability and concomitant MMP-9 upregulation suggests that these events are critical neuropathogenic events. Because of the dependence of MMP-9 induction and BBB permeability during neurologic diseases on TLR4, the role of TLR4 during VEEV TC-83 infection was examined.

Previously, intranasal VEEV TC-83 infection has been shown to cause increased BBB permeability and symptomatic infections in C57BL/6 mice, Ifit1 knockout mice [9] and TLR4 WT mice [36] with the latter two

---

**Figure 6.** Immune cell populations in the brains of VEEV TC-83-infected TLR4 WT mice and TLR4 mut mice at day 6 PI. The immune cell populations in the brains of uninfected and TC-83-infected mice were determined by FACS analysis 6 days after infection. The percentage (a) and number (b) of CD45 hi cells and (c-d) NK cells. The percentage (e) and number (f) of CD3+ or CD19+CD45 hi cells. The percentage (g) and number (h) of CD3+ cells that were CD4+ or CD8+. The percentage (i) and number (j) of CD4+ cells that were CD69+ or CD69+IFNγ+. The percentage (k) and number (l) of CD8+ cells that were CD69+ or CD69+IFNγ+. Data are presented as mean ± SEM (n = 5 mice per group). Statistically significant differences are indicated as **, p < 0.01. Statistical significance was evaluated by unpaired two-tailed Student’s t-tests or Mann-Whitney tests.
developing neurological symptoms and mortality. Here, TLR4\textsuperscript{WT} mice in parallel with TLR4\textsuperscript{mut} mice were used to determine the effects of TLR4 on the susceptibility of mice to disease as a result of intranasal VEEV TC-83 infection. This model was used because VEEV TC-83 infection in TLR4\textsuperscript{WT} mice results in increased BBB permeability [36] as does wild-type VEEV infection in mice [12]. In addition, the brain pathology in this model is similar to the brain pathology seen in mice infected with other VEEV strains, including meningoencephalitis, gliosis and multifocal neuropil vacuolation [29,37–39]. However, VEEV TC-83 infection is limited to the brain with minimal spread outside the CNS after aerosol or intranasal exposure, thus limiting the effects of systemic inflammation on the BBB, in contrast to VEEV TrD infection. Therefore, VEEV TC-83 infection in C3H mice remaining relatively restricted to the CNS while still mediating neurologic disease provides a better model, compared with using VEEV TrD, to examine the role of BBB permeability during CNS infection with VEEV and the mechanisms by which increased BBB permeability is induced. Intranasal exposure of TLR4\textsuperscript{WT} mice and TLR4\textsuperscript{mut} mice to VEEV TC-83 demonstrate that TLR4\textsuperscript{mut} mice are less susceptible to disease and that TLR4 plays a role in mediating this disease. The difference in susceptibility of TLR4\textsuperscript{mut} mice to disease caused by VEEV TC-83 infection was not because of a decrease in viral replication in the brain. Viral titers were decreased in the cortices of infected TLR4\textsuperscript{mut} mice compared with infected TLR4\textsuperscript{WT} mice at days 1 and 6 PI and increased at days 2 and 8 PI suggesting there might be slight differences in the kinetics of virus replication in the brains of these mice. However, these differences were not statistically significant suggesting that there are other factors associated with increased survival of TLR4\textsuperscript{mut} mice.

One potential mechanism of the decreased VEEV-related disease that we observed in TLR4\textsuperscript{mut} mice as compared to wild-type mice is the reduced induction of BBB permeability as demonstrated by NaF and DEX-680 extravasation. Our data are consistent with the findings of a previous study, which showed that inhibiting the induction of BBB permeability with a broad spectrum MMP inhibitor, GM6001, delayed the onset of disease and decreased mortality in mice infected with wild-type VEEV [12]. However, our study expands on earlier work by demonstrating that upregulation of MMP-9 and the induction of BBB permeability are dependent on TLR4 during VEEV TC-83 infection in mice. The induction of BBB permeability and MMP-9 to lesser extents in infected TLR4\textsuperscript{mut} mice compared with infected TLR4\textsuperscript{WT} mice and the relative increased induction of MMP-9 compared with MMP-2 in infected TLR4\textsuperscript{WT} mice suggest that MMP-9 is the major mediator of increased BBB permeability during VEEV infection. During ischemic stroke in mice, MMP-2 and MMP-9 have different roles in BBB disruption where MMP-2 does not contribute to acute tissue damage as evidenced by the absence of neuroprotection of MMP-2 knockouts [40]. In contrast, MMP-9 knockout provides strong protection in ischemic stroke mouse models [17]. Additional evidence comes from studies in which MMP-9, but not MMP-2, is neurotoxic in hippocampal slice preparations [41] and from work showing that MMP-9 knockout mice are less susceptible to disease caused by peripheral WNV exposure compared with wild-type
mice [14]. Therefore, our results and corroborating studies in other systems indicate that MMP-9 is a critical mediator of BBB permeability and, potentially, neuronal damage during CNS infections with VEEV.

In addition to the lack of significant MPP-9 induction, the lesser inductions of ICAM-1, CCL-2, IFN-γ and BBB permeability in infected TLR4mut mice suggested there could be a difference in the population of infiltrating immune cells in the brain. NK cells were of particular interest because they release IFN-γ and have been suggested to have a role in mediating VEEV TC-83 pathogenesis in C3H/HeN mice [30]. Not only were there no differences in NK cell number in the brains of the two infected substrains, there were no differences in other immune cell populations examined with the exception of more B cells in the infected TLR4mut mice. In both TLR4WT and TLR4mut mice, there was still a significant induction of BBB permeability, ICAM-1, MMP-2 and CCL-2 in the brains during VEEV TC-83 infection. Therefore, the induction of these factors suggests that both the TLR4WT and TLR4mut mice have similar immune responses in the brain at day 6 PI. Additional studies to include more time points and functional assays will have to be performed to determine if the phenotypes of infiltrating immune cells are altered as a result of defective TLR4 signaling.

The combination of impaired TLR4 signaling in the TLR4mut mice with significantly less IFN-γ induction in the brains suggests that these may play a role in neurotoxicity and inflammation-induced neurodegeneration. A study using organotypic hippocampal slice cultures from rats in the absence of infiltrating leukocytes found that activating TLR4 with LPS induced the stable release of proinflammatory cytokines (IL-1β, TNF-α and IL-6; IFN-γ was not significantly induced) while IFN-γ did not. Additionally, exposure to LPS or IFN-γ alone resulted in released nitric oxide (NO) through upregulated inducible nitric oxide synthase (iNOS). However, LPS or IFN-γ exposure alone only moderately affected intrinsic neuronal excitability and gamma oscillations. Strikingly though, co-exposure to LPS and IFN-γ resulted in a higher magnitude of NO release and iNOS expression as well as massive neuronal dysfunction and death to the point that the slice cultures disintegrated and neuronal activity was completely absent. These studies showed that TLR4-activated microglia require concomitant IFN-γ signaling to induce massive inflammatory neurodegeneration [42]. In addition, iNOS knockout mice infected with wild-type VEEV have increased survival times [39], but these mice are still susceptible to LPS-induced death [43]. Therefore, the lack of mortality and disease in the TC-83-infected TLR4mut mice suggests that VEEV infection may require the coactivation of TLR4 and IFN-γ receptors to mediate neurologic disease, potentially independent of iNOS, despite the presence of infiltrating leukocytes and pro-inflammatory cytokines. Future studies with VEEV will examine the coactivation of these receptors on NO release and neurodegeneration both in situ and in vivo.

Excessive inflammatory responses are present in severe diseases caused by a wide variety of viruses, including respiratory syncytial virus (RSV) [44], influenza A virus (IAV) [45], Ebola virus (EBOV) [46], dengue virus (DENV) [47] and severe acute respiratory syndrome coronavirus [48]. The role of TLR4 in the pathogenesis of some of these viral diseases is demonstrated by the reduced induction of cytokines and chemokines as a result of treatment with TLR4 antagonists [49–53]. Furthermore, treatment with these TLR4 antagonists prevented lethal EBOV [53] and IAV infection [50–52] in mice demonstrating the therapeutic potential of inhibiting TLR4 during viral infections. However, TLR4 knockout mice have either similar survival rates or more severe disease than wild-type mice when infected with EBOV [53] and, in some cases, IAV [54] suggesting that some degree of TLR4 signaling is required for the protective response of TLR4 antagonists against these viruses. Therefore, TLR4 is an attractive target for the development of therapeutics against these viruses and VEEV.

VEEV could be mediating TLR4 activation through one of the viral proteins, damage-associated molecular patterns (DAMPs), or both. The RSV fusion protein [55], EBOV glycoprotein [56,57] and DENV nonstructural protein 1 [49] all activate TLR4. In contrast with these viruses, IAV activates TLR4 by host DAMPs, including HMGB1 [51] and oxidized phospholipids [58]. Intracranial inoculation of VEEV replicon particles into the brains of mice induce BBB permeability, but UV-inactivated VEEV replicon particles do not, suggesting that viral RNA replication is required for BBB permeability induction [59]. This lack of BBB permeability induction by UV-inactivated VEEV replicon particles and the dependence of BBB permeability induction on TLR4 suggests that if a viral protein is activating TLR4, it is either a nonstructural protein or virus replication is needed to produce a sufficient amount of VEEV glycoproteins to activate TLR4 to mediate BBB permeability. In addition, intranasal inoculation of VEEV replicon particles mediating BBB permeability in the cortex despite being restricted to the olfactory bulb [12] suggests that there is a signal that is disseminated through the brain.
Potential mediators of TLR4 activation include HMGB1 and other DAMPs. HMGB1 is a non-histone nuclear protein that can function as a pathogenic inflammatory response in a number of conditions in the brain, including epilepsy [60], septic shock [61], ischemia [62], traumatic brain injury [63], Parkinson’s disease [64], Alzheimer’s disease [65] and multiple sclerosis [66]. After neuronal injury, significant amounts of HMGB1 are passively released from the nucleus and into the extracellular space [67]. In addition, HMGB1 is actively secreted by neurons and glia upon inflammasome activation in neuroinflammatory conditions. In the extracellular space, HMGB1 can alter synaptic function in the brain and mediate inflammation [68]. Furthermore, HMGB1 has been shown to activate TLR4 to induce MMP-9 upregulation following cerebral ischemia [25]. Therefore, the decrease in disease of the TLR4mut mice during VEEV TC-83 infection might in part be mediated by a decrease in HMGB1 driven pro-inflammatory effects, although this remains to be experimentally demonstrated.

One limitation of these studies is that the substrains of mice were purchased from different vendors, which could have confounding effects on the results of the experiments. For example, there are significant differences in the bacterial and viral components of the gut microbiome between the same strain of mice purchased from different vendors [69]. Additional confounding effects could result from potentially different diets fed by different vendors, the effects of potentially different maternal behaviors of the substrains and potential genetic drift of the substrains. These potential confounds support the need to perform these studies with WT VEEV in WT C57BL/6 mice and TLR4 knockout mice on the same genetic background from the same vendor. However, the established role of TLR4 in regulating MMP-9, which are also demonstrated in these studies, supports the results from the present studies.

In summary, our findings demonstrate that TLR4 is an important mediator of disease pathogenesis in C3H mice infected with VEEV TC-83 as TLR4mut mice are less susceptible to disease during VEEV TC-83 infection. In addition, the induction of BBB permeability and upregulation of MMP-9 during CNS VEEV TC-83 infection are dependent on TLR4. However, because induction of BBB is a relatively late and critical event in viral encephalitis, TLR4 may be a potential target for the development of therapeutics for encephalitic alphaviruses. Further studies are needed to understand the precise mechanisms by which TLR4 mediates encephalitic disease during VEEV infection.

Acknowledgments

This research was performed while Dr. Bradley S. Hollidge held an NRC Research Associateship award at the U.S. Army Medical Research Institute of Infectious Diseases and was funded by the Defense Threat Reduction Agency through the NRC Research Associateship Program in Chemical and Biological Defense. Opinions, conclusions, and recommendations are ours and are not necessarily endorsed by the U.S. Army or the Department of Defense.

Disclosure statement

The authors have no competing interests.

Funding

This work was supported by the Defense Threat Reduction Agency.

ORCID

Bradley S. Hollidge http://orcid.org/0000-0002-1740-9158

References

[1] Griffin DE. Alphaviruses. In: Knipe D, Howley PM, editors. Fields virology. 4 ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2001. p. 917–1662.
[2] Zacks MA, Paessler S. Encephalitic alphaviruses. Vet Microbiol. 2010;140(3–4):281–286.
[3] Weaver SC, Ferro C, Barrera R, et al. Venezuelan equine encephalitis. Annu Rev Entomol. 2004;49 (1):141–174.
[4] Rusnak JM, Dupuy LC, Niemuth NA, et al. Comparison of aerosol- and percutaneous-acquired venezuelan equine encephalitis in humans and nonhuman primates for suitability in predicting clinical efficacy under the animal rule. Comp Med. 2018;68 (5):380–395.
[5] Bowen GS, Fashinell TR, Dean PB, et al. Clinical aspects of human Venezuelan equine encephalitis in Texas. Bull Pan Am Health Organ. 1976;10(1):46–57.
[6] Honnold SP, Mossel EC, Dupuy LC, et al. Alphavirus encephalitides. In: Bozue J, Cote CK, Glass PJ, editors. Medical aspects of biological warfare. Fort Sam Houston, Texas: Borden Institute (Office of the Surgeon General); 2018:479–516.
[7] Hanson RP, Sulkin SE, Beuscher EL, et al. Arbovirus infections of laboratory workers. Extent of problem emphasizes the need for more effective measures to reduce hazards. Science. 1967;158(3806):1283–1286.
[8] Slepushkin AN. [Epidemiological studies on case of Venezuelan equine encephalomyelitis in a laboratory]. Vopr Virusol. 1959;4(3):311–314.
[9] Cain MD, Salimi H, Gong Y, et al. Virus entry and replication in the brain precedes blood-brain barrier disruption during intranasal alphavirus infection. J Neuroimmunol. 2017;308:118–130.
[10] Ryzhikov AB, Tkacheva NV, Sergeev AN, et al. Venezuelan equine encephalitis virus propagation in the olfactory tract of normal and immobilized mice. Biomed Sci. 1991;2(6):607–614.

[11] Steele KE, Davis KJ, Stephan K, et al. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice. Vet Pathol. 1998;35(5):386–397.

[12] Schafer A, Brooke CB, Whitmore AC, et al. The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J Virol. 2011;85(20):10682–10690.

[13] Walters AW, Kujawa MR, Albe JR, et al. Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats. Virology. 2019;526:173–179.

[14] Wang P, Dai J, Bai F, et al. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. J Virol. 2008;82(18):8978–8985.

[15] Wang T, Town T, Alexopoulos L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis Nat Med. 2004;10(12):1366–1373.

[16] Okada T, Kawakita F, Nishikawa H, et al. Selective Toll-like receptor 4 antagonists prevent acute blood-brain barrier disruption after subarachnoid hemorrhage in mice. Mol Neurobiol. 2019;56(2):976–985.

[17] Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001;21(19):7724–7732.

[18] Suzuki H, Ayer R, Sugawara T, et al. Protective effects of recombinant osteopontin on early brain injury after subarachnoid hemorrhage in rats. Crit Care Med. 2010;38(2):612–618.

[19] Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27(4):697–709.

[20] Feiler S, Plesnila N, Thal SC, et al. Contribution of matrix metalloproteinase-9 to cerebral edema and functional outcome following experimental subarachnoid hemorrhage. Cerebrovasc Dis. 2011;32(3):289–295.

[21] Shigemori Y, Katayama Y, Mori T, et al. Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochir Suppl. 2006;96:130–133.

[22] Deng J, Zhang J, Feng C, et al. Critical role of matrix metalloprotease-9 in chronic high fat diet-induced cerebral vascular remodelling and increase of ischaemic brain injury in micedagger. Cardiovasc Res. 2014;103(4):473–484.

[23] Suofu Y, Clark JF, Broderick JP, et al. Matrix metalloproteinase-2 or −9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion. Neuroscience. 2012;212:180–189.

[24] Min H, Hong J, Cho IH, et al. TLR2-induced astrocyte MMP9 activation compromises the blood brain barrier and exacerbates intracerebral hemorrhage in animal models. Mol Brain. 2015;8(1):23.

[25] Qiu J, Xu J, Zheng Y, et al. High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke. 2010;41(9):2077–2082.

[26] Han YW, Choi JY, Uyangaa E, et al. Distinct dictation of Japanese encephalitis virus-induced neuroinflammation and lethality via triggering TLR3 and TLR4 signaling pathways. PLoS Pathog. 2014;10(9):e1004319.

[27] Kurt-Jones EA, Chan M, Zhou S, et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A. 2004;101(5):1315–1320.

[28] Kulcsar KA, Griffin DE. T cell-derived interleukin-10 is an important regulator of the Th17 response during lethal alphavirus encephalomyelitis. J Neuroimmunol. 2016;295-296:60–67.

[29] Julander JG, Skirpustunas R, Siddharthan V, et al. C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res. 2008;78(3):230–241.

[30] Taylor K, Kokolossova O, Patterson M, et al. Natural killer cell mediated pathogenesis determines outcome of central nervous system infection with Venezuelan equine encephalitis virus in C3H/HeN mice. Vaccine. 2012;30(27):4095–4105.

[31] Politarak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282(5396):2085–2088.

[32] Hubbard AK, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med. 2000;28(9):1379–1386.

[33] Guo F, Xu D, Lin Y, et al. Chemokine CCL2 contributes to BBB disruption via the p38 MAPK signaling pathway following acute intracerebral hemorrhage. Faseb J. 2020;34(1):1872–1884.

[34] Chai Q, He WQ, Zhou M, et al. Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/chemokines induced by rabies virus infection. J Virol. 2014;88(9):4698–4710.

[35] Too JK, Ball HJ, McGregor IS, et al. The pro-inflammatory cytokine interferon-gamma is an important driver of neuropathology and behavioural sequelae in experimental pneumoconcoal meningitis. Brain Behav Immun. 2014;40:252–268.

[36] Bocan TM, Stafford RG, Brown JL, et al. Characterization of brain inflammation, apoptosis, hypoxia, blood-brain barrier integrity and metabolism in venezuelan equine encephalitis virus (veev tc-83) exposed mice by in vivo positron emission tomography imaging. Viruses. 2019;11(11):11.

[37] Charles PC, Tugovitch J, Davis NL, et al. Immunopathogenesis and immune modulation of Venezuelan equine encephalitis virus-induced disease in the mouse. Virology. 2001;284(2):190–202.

[38] Jackson AC, SenGupta SK, Smith JF Pathogenesis of Venezuelan equine encephalitis virus infection in mice and hamsters. Vet Pathol. 1991;28(5):410–418.

[39] Schoneboom BA, Catlin KM, Marty AM, et al. Inflammation is a component of neurodegeneration in
response to Venezuelan equine encephalitis virus infection in mice. J Neuroimmunol. 2000; 109(2):132–146.

[40] Asahi M, Sumii T, Fini ME, et al. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport. 2001; 12(13):3003–3007.

[41] Jourquin J, Tremblay E, Decanis N, et al. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci. 2003; 18(6):1507–1517.

[42] Papageorgiou IE, Lewen A, Galow LV, et al. TLR4-activated microglia require IFN-gamma to induce severe neuronal dysfunction and death in situ. Proc Natl Acad Sci U S A. 2016; 113(1):212–217.

[43] Laubach VE, Shesely EG, Smithies O, et al. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A. 1995; 92(23):10688–10692.

[44] Russell CD, Unger SA, Walton M, et al. The Human immune response to respiratory syncytial virus infection. Clin Microbiol Rev. 2017; 30(2):481–502.

[45] Guo XJ, Thomas PG. New fronts emerge in the influenza cytokine storm. Semin Immunopathol. 2017; 39(5):541–550.

[46] Bixler SL, Goff AJ. The role of cytokines and chemokines in filovirus infection. Viruses. 2015; 7(10):5489–5507.

[47] Srikatkhachorn A, Mathew A, Rothman AL. Immune-mediated cytokine storm and its role in severe dengue. Semin Immunopathol. 2017; 39(5):563–574.

[48] Channappanavar R, Perlman S. Pathogenic human coronaviruses infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39(5):529–539.

[49] Modhiran N, Watterson D, Muller DA, et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med. 2015; 7(304):304ra142.

[50] Perrin-Cocon I, Aublin-Gex A, Sestito SE, et al. TLR4 antagonist F7P inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep. 2017; 7(1):40791.

[51] Shirey KA, Lai W, Patel MC, et al. Novel strategies for targeting innate immune responses to influenza. Mucosal Immunol. 2016; 9(5):1173–1182.

[52] Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013; 497(7450):498–502.

[53] Younan P, Ramanathan P, Graber J, et al. The Toll-like receptor 4 antagonist eritoran protects mice from lethal filovirus challenge. mBio. 2017; 8(2). DOI: 10.1128/mBio.00226-17

[54] Morales-Nebreda L, Mutlu GM, Scott Budinger GR, et al. Loss of TLR4 does not prevent influenza A-induced mortality. Am J Respir Crit Care Med. 2014; 189(10):1280–1281.

[55] Rallabandi P, Phillips RL, Boukhvalova MS, et al. Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2. mBio. 2012; 3(4). DOI: 10.1128/mBio.00218-12.

[56] Escudero-Perez B, Volchkova VA, Dolnik O, et al. Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog. 2014; 10(11):e1004509.

[57] Iampietro M, Younan P, Nishida A, et al. Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. PLoS Pathog. 2017; 13(5):e1006397.

[58] Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008; 133(2):235–249.

[59] Schafer A, Whittmore AC, Konopka JL, et al. Replicon particles of Venezuelan equine encephalitis virus as a reductionist murine model for encephalitis. J Virol. 2009; 83(9):4275–4286.

[60] Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in icotgenesis and can be targeted to reduce seizures. Nat Med. 2010; 16(4):413–419.

[61] Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285(5423):248–251.

[62] Kim JB, Sig Choi J, Yu YM, et al. HMG1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci. 2006; 26(24):6413–6421.

[63] Okuma Y, Liu K, Wake H, et al. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol. 2012; 72(3):373–384.

[64] Sasaki T, Liu K, Agari T, et al. Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease. Exp Neurol. 2016; 275(Pt 1):220–231.

[65] Fujita K, Motoki K, Tagawa K, et al. HMG1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer’s disease. Sci Rep. 2016; 6(1):31895.

[66] Andersson A, Covacu R, Sunnemark D, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 2008; 84(5):1248–1255.

[67] Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418(6894):191–195.

[68] Ravizza T, Terrone G, Salamone A, et al. High mobility group box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy. Brain Behav Immun. 2018; 72:14–21.

[69] Rasmussen TS, de Vries I, Kot W, et al. Mouse vendor influence on the bacterial and viral gut composition exceeds the effect of diet. Viruses. 2019; 11(5):435.